17 results found.

Adenocarcinoma of the Prostate Clinical Trial using EPISPOT detection of the number of circulating cells; CellSearch detection of the number of circulating, functional, prostate cells

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 18 years or older.
- The Pre-treatment Detection of Circulating, Functional, Prostate Cells Among Adenocarcinoma Patients: an Evaluation of the EPISPOT Technique.
EPISPOT detection of the number of circulating cells; CellSearch detection of the number of circulating, functional, prostate cells

Prostate Cancer Clinical Trial using LHRH; Docetaxel; Conformal RT

Proton Collaborative Group - Recruiting 18 years to 75 years.
- Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate.
LHRH; Docetaxel; Conformal RT

Prostate Cancer Clinical Trial using Proton Radiation Hypofractionation; Proton Radiation Standard Fractionation

Proton Collaborative Group - Recruiting 18 years or older.
- A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation With Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate.
Proton Radiation Hypofractionation; Proton Radiation Standard Fractionation

Prostate Cancer Clinical Trial using Proton Radiation; Androgen Suppression Therapy

Proton Collaborative Group - Recruiting 18 years or older.
- Phase III Study of Mildly Hypo-fractionated Image Guided Proton Beam Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate.
Proton Radiation; Androgen Suppression Therapy

Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistan Clinical Trial using sipuleucel-T; external beam radiation therapy; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years or older.
- Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer.
sipuleucel-T; external beam radiation therapy; laboratory biomarker analysis

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region..

Prostate Cancer Clinical Trial using Cancer Macrobead placement in abdominal cavity

The Rogosin Institute - Recruiting 18 years or older.
- An Open-Label, Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose- Agarose Macrobeads in the Treatment of Patients With Castration-Resistant Prostate Cancer Resistant to Docetaxel.
Cancer Macrobead placement in abdominal cavity

Prostate Adenocarcinoma Clinical Trial using Stereotactic Ablative Radiation

Sunnybrook Health Sciences Centre - Recruiting 18 years or older.
- Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer.
Stereotactic Ablative Radiation

Adenocarcinoma of Prostate, or Progression of Prostate Cancer Clinical Trial using Cabazitaxel; Pelvic radiotherapy; prostate radiotherapy

UNICANCER - Recruiting 18 years to 75 years.
- A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse.
Cabazitaxel; Pelvic radiotherapy; prostate radiotherapy

Prostate Cancer Clinical Trial using Proton Beam Therapy; Questionnaire

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Trial of Hypofractionated Proton Beam Therapy in Men With Localized Prostate Adenocarcinoma.
Proton Beam Therapy; Questionnaire

Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Clinical Trial using cholecalciferol; genistein; placebo; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy.
cholecalciferol; genistein; placebo; laboratory biomarker analysis; pharmacological study

Prostate Cancer Clinical Trial using Cabazitaxel; Intensity Modulated Radiation Therapy (IMRT); Anti-Androgen Therapy: Bicalutamide; Luteinizing Hormone-Releasing Hormone (LHRH) Agonist

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I Trial of Weekly Cabazitaxel With Concurrent Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy for the Treatment of Locally Advanced High Risk Adenocarcinoma of the Prostate.
Cabazitaxel; Intensity Modulated Radiation Therapy (IMRT); Anti-Androgen Therapy: Bicalutamide; Luteinizing Hormone-Releasing Hormone (LHRH) Agonist

Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage Clinical Trial using stereotactic body radiation therapy; quality-of-life assessment; laboratory biomarker analysis

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- High-Dose Stereotactic Body Radiation Therapy in Treating Patients With Low-, Intermediate-, or High-Risk Localized Prostate Cancer.
stereotactic body radiation therapy; quality-of-life assessment; laboratory biomarker analysis

Prostate Cancer Clinical Trial using hypofractionation

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate.
hypofractionation

Adenocarcinoma of the Prostate Clinical Trial using Radiation Therapy; Androgen Deprivation Therapy (ADT)

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate.
Radiation Therapy; Androgen Deprivation Therapy (ADT)

Adenocarcinoma of the Prostate Clinical Trial using Androgen suppression plus radiation therapy

McGill University - Recruiting 18 years to 85 years.
- A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate.
Androgen suppression plus radiation therapy